Title: | Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation : 2-year results of the C-OPERA study, a phase III randomised trial |
Authors: | Atsumi, Tatsuya Browse this author →KAKEN DB |
Tanaka, Yoshiya Browse this author →KAKEN DB |
Yamamoto, Kazuhiko Browse this author →KAKEN DB |
Takeuchi, Tsutomu Browse this author →KAKEN DB |
Yamanaka, Hisashi Browse this author →KAKEN DB |
Ishiguro, Naoki Browse this author →KAKEN DB |
Eguchi, Katsumi Browse this author →KAKEN DB |
Watanabe, Akira Browse this author →KAKEN DB |
Origasa, Hideki Browse this author →KAKEN DB |
Yasuda, Shinsuke Browse this author →KAKEN DB |
Yamanishi, Yuji Browse this author |
Kita, Yasuhiko Browse this author |
Matsubara, Tsukasa Browse this author |
Iwamoto, Masahiro Browse this author →KAKEN DB |
Shoji, Toshiharu Browse this author |
Togo, Osamu Browse this author |
Okada, Toshiyuki Browse this author |
van der Heijde, Désirée Browse this author |
Miyasaka, Nobuyuki Browse this author →KAKEN DB |
Koike, Takao Browse this author →KAKEN DB |
Issue Date: | Aug-2017 |
Publisher: | BMJ Publishing Group |
Journal Title: | Annals of the rheumatic diseases |
Volume: | 76 |
Issue: | 8 |
Start Page: | 1348 |
End Page: | 1356 |
Publisher DOI: | 10.1136/annrheumdis-2016-210246 |
Abstract: | Objectives: To investigate the clinical impact of 1-year certolizumab pegol (CZP) therapy added to the first year of 2-year methotrexate (MTX) therapy, compared with 2-year therapy with MTX alone. Methods: MTX-naïve patients with early rheumatoid arthritis (RA) with poor prognostic factors were eligible to enter Certolizumab-Optimal Prevention of joint damage for Early RA (C-OPERA), a multicentre, randomised, controlled study, which consisted of a 52-week double-blind (DB) period and subsequent 52-week post treatment (PT) period. Patients were randomised to optimised MTX+CZP (n=159) or optimised MTX+placebo (PBO; n=157). Following the DB period, patients entered the PT period, receiving MTX alone (CZP+MTX→MTX; n=108, PBO+MTX→MTX; n=71). Patients who flared could receive rescue treatment with open-label CZP. Results: 34 CZP+MTX→MTX patients and 14 PBO+MTX→MTX patients discontinued during the PT period. From week 52 through week 104, significant inhibition of total modified total Sharp score progression was observed for CZP+MTX versus PBO+MTX (week 104: 84.2% vs 67.5% (p<0.001)). Remission rates decreased after CZP discontinuation; however, higher rates were maintained through week 104 in CZP+MTX→MTX versus PBO+MTX→MTX (41.5% vs 29.3% (p=0.026), 34.6% vs 24.2% (p=0.049) and 41.5% vs 33.1% (p=0.132) at week 104 in SDAI, Boolean and DAS28(erythrocyte sedimentation rate) remission. CZP retreated patients due to flare (n=28) showed rapid clinical improvement. The incidence of overall adverse events was similar between groups. Conclusions: In MTX-naïve patients with early RA with poor prognostic factors, an initial 1 year of add-on CZP to 2-year optimised MTX therapy brings radiographic and clinical benefit through 2 years, even after stopping CZP. |
Rights: | This article has been accepted for publication in Atsumi T, Tanaka Y, Yamamoto K, et al., Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial, Annals of the Rheumatic Diseases 2017;76:1348-1356, following peer review and can also be viewed on the journal's website at http://ard.bmj.com. |
http://creativecommons.org/licenses/by-nc/4.0/ |
Type: | article |
URI: | http://hdl.handle.net/2115/67068 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|